
BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers
BUSINESS WIRE)--BioLife Plasma Services, part of Takeda (TSE:4502/NYSE:TAK), today announced that it has begun introducing the new Fresenius Kabi Adaptive Nomogram across its U.S. network of plasma donation centers. The new Adaptive Nomogram is used on the Aurora Xi Plasmapheresis System, which is in more than half of BioLife's U.S. plasma donation centers. This new technology will be running in all BioLife donation centers using the Aurora Xi Plasmapheresis System by the end of December 2025.
The new Adaptive Nomogram technology leverages a plasma donor's unique body attributes, resulting in a more personalized plasma donation and a potential increase in the average amount of plasma collected. Three BioLife plasma donation centers participated in Fresenius Kabi's clinical trial to provide data for the U.S. FDA's premarket review of the new technology. The data collected by BioLife during the clinical trial successfully demonstrated a ~11.5% increase in plasma collected on average per donor with the Aurora Xi Plasmapheresis System. Participation in the clinical trial enabled a more rapid launch plan for BioLife.
'We're the first company to introduce this new Adaptive Nomogram technology in our plasma donation centers, which is a demonstration of our commitment to investing in the latest technology to increase operational efficiency while maintaining the safety of our plasma donors,' said Hema Tallman, SVP and Global Head of BioLife Plasma Services. 'This rollout will also continue helping us strengthen our plasma supply and provide people in need with the life-sustaining and lifesaving medicines that Takeda produces from plasma.'
'Fresenius Kabi is pleased to see the implementation of our Adaptive Nomogram at BioLife locations in the U.S. and believe it can play a key role in supporting plasma centers and the critical therapies they provide to patients,' said Dr. Christian Hauer, President, MedTech at Fresenius Kabi. 'Such innovation is aimed at advancing efficiency and sustainability of plasma collection for customers by leveraging donor data to deliver one of the most personalized and optimized plasma collection processes available today."
With the addition of Fresenius Kabi's Adaptive Nomogram and the already deployed Haemonetics Persona Nomogram, BioLife anticipates having new personalized nomograms rolled out to 100% of its plasma donation centers by end of March 2026.
About BioLife Plasma Services
BioLife Plasma Services is a trusted leader in the collection of high-quality plasma required to produce lifesaving and life-sustaining medicines for hundreds of thousands of people with rare and serious health conditions and in critical care settings. Plasma donations from more than 270 BioLife centers in the United States and Europe are essential to Takeda developing more than 20 approved brands of medicine made from plasma. BioLife Plasma Services is part of Takeda(TSE:4502/NYSE:TAK), a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan. For more information, visit BioLifePlasma.com.
About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.
Important Notice
For the purposes of this notice, 'press release' means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ('Takeda') regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, 'Takeda' is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words 'we', 'us' and 'our' are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as 'targets', 'plans', 'believes', 'hopes', 'continues', 'expects', 'aims', 'intends', 'ensures', 'will', 'may', 'should', 'would', 'could', 'anticipates', 'estimates', 'projects' or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda's operations and the timing of any such divestment(s); and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda's future results.
Medical Information
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
2 hours ago
- Business Wire
ATKORE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Atkore Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ('KSF'), announces that KSF has commenced an investigation into Atkore Inc. (NYSE: ATKR). In July 2024, the Company was named as a defendant in a number of civil antitrust lawsuits alleging that, from at least April 1, 2021, it and other U.S.-based PVC Pipe manufacturers conspired to artificially inflate the price of PVC Pipes through the exchange of competitively sensitive business information regarding PVC Pipe pricing and sales through an industry newsletter called Oil Price Information Service, LLC ('OPIS'), in violation of federal antitrust laws. Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information in violation of federal securities laws, which remains ongoing. KSF's investigation is focusing on whether Atkore's officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws. If you have information that would assist KSF in its investigation, or have been a long-term holder of Atkore shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-833-938-0905 or email KSF Managing Partner Lewis Kahn ( or visit to learn more. About Kahn Swick & Foti, LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, New Jersey, and a representative office in Luxembourg. To learn more about KSF, you may visit
Yahoo
2 hours ago
- Yahoo
Circle Goes Full Circle
By sheer luck, I had an opening bell media hit with NYSE TV this last Thursday, the day Circle listed as CRCL. The NYSE studio is upstairs at gallery level. I'd first visited the NYSE on the same gallery balcony as a boy with my Dad. I remember getting the impression that IBM was a huge company that represented the future. Circle staff and guests filed in at 9:15, a much larger delegation than most bell-ringings. Not only was the floor packed, but both galleries were full. As the applause started, precisely at 9:29:30, everything else stopped. This wasn't the usual opening bell tea ceremony. NYSE President Lynn Martin stood beside an air-punching Circle CEO Jeremy Allaire, and the specialists, floor brokers, and other floor inhabitants joined in the cacophony. The energy took over the whole floor in a way that felt exceptional. I asked, cheekily, to the NYSE TV folks which specialist booth would trade CRCL. No one had any idea what I was talking about. The producer decided to move our hit to the floor with a handheld microphone and change our subject from bitcoin to stablecoins on the fly. That was fine—plenty to say about stablecoins. Standing within feet of Jeremy Allaire on the floor next to the bell balcony, doing our five-minute segment, it was pure electricity. It was the feeling when you finish a marathon and a beaming volunteer places a medal around your neck. Accomplishment and validation. This was a moment enabled by a friendlier SEC and coincident with meaningful blockchain legislation, but it didn't have the vibe of MSTR rapture or youthful DeFi exuberance. It felt mature and financial--adults celebrating. USDC sprang to life in September 2018, just before a local peak in U.S. interest rates. In retrospect, it was a handy time to launch, when carry (yield from backing assets) was positive but yield expectations in crypto (whose practitioners mostly grew up in a zero interest rate world) remained low. When COVID hit, in 2020, ZIRP (Zero-Interest-Rate-Policy) returned suddenly, threatening the business model, but prompting crypto adoption and experimentalism. When the Fed aggressively raised rates in 2022 to help metabolize $5 trillion in COVID fiscal stimulus, stablecoins faced the opposite combination of supportive and threatening forces: higher carry revenues, but traumatized markets. Circle's failed SPAC attempt spanned this transition. Announced in July 2021 when 3-month yields were 0.05%, the Concord Acquisition deal was renegotiated in February 2022 (as rates began their historic climb) and ultimately terminated in December 2022—right as rates hit 4.42%. The SEC never declared the S-4 registration statement effective. The transaction "timed out" waiting for regulatory approval, just as the underlying economics of Circle's business were being boosted by soaring rates. Now, several years into a 4-5% rate environment, the model has adapted and appears to be working. USDC holders can receive "rewards" on Coinbase that are similar to risk-free yields. On-chain cash holdings and collateral can be enhanced with tokenized treasuries. The GENIUS Act on stablecoins appears in good shape for passage, opening up the market for greater stablecoin adoption and participation. The U.S. government has a new potential multi-trillion dollar customer for U.S. treasuries, providing much-needed demand for U.S. debt, which has become a chess piece in global trade. Circle (and other stablecoin issuers) are enjoying a good carry scenario, although near-term profitability has significant interest rate risk, now under the watchful scrutiny of CRCL shareholders and analysts. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Wire
2 hours ago
- Business Wire
RGA and SOA Research Institute Release Comprehensive Study on Retirement Readiness in Japan
TOKYO--(BUSINESS WIRE)--The Society of Actuaries (SOA) Research Institute, in collaboration with Reinsurance Group of America, Incorporated (NYSE: RGA), a leading global life and health reinsurer, today released a new report titled 'Retirement Readiness in Japan: Financial Security and Risk Perceptions.' The study provides critical insights into the evolving retirement landscape in Japan, offering valuable information for insurers, policymakers, and financial advisors. This research underscores the urgent need for innovative retirement solutions that address both income security and health-related financial risks. Share The study, based on a November 2024 joint consumer survey conducted by the SOA and RGA among 750 Japanese respondents across three age groups (Prime Age Workers: ages 30-45, Pre-Retirees: ages 46-59, and Retirees: ages 60-75), reveals a maturing retirement system facing significant demographic pressures. With nearly 29% of Japan's population aged 65 or older 1, the need for robust retirement planning and financial products is more critical than ever. Key findings: Financial Literacy: 17% of respondents reported no knowledge at all about investment and financial products, and 42% indicated 'not very knowledgeable.' Generational Divide in Planning: Retirees show significantly higher engagement in retirement planning compared to younger cohorts, with 37% of Prime Age Workers and 45% of Pre-Retirees not having done any retirement planning. Post-Retirement Concerns about Factors Outside of Individual's Control Dominate: 90% of respondents consider tax increase and impact of an aging society on government support as their top concerns. Source of Retirement Income: Prime Age Workers and Pre-Retirees are not confident that their retirement savings are sufficient; 89% of them expect to rely on full- or part-time job earnings as part of their retirement income. Preference on Financial Products with Guaranteed or Fixed Income: Guaranteed income for life (43%) and fixed income throughout retirement (39%) are considered top financial/investment product features for retirement income, indicating preference for risk-averse options. Significant Interest in Annuity Products: 73% of respondents expressed interest in annuities with increased payments for critical illness or disability or tax-deferred annuity (65%). Improved Engagement in Retirement Planning Since 2018: Overall engagement has improved. Willingness to buy lifetime income products increased from 22% in 2018 to 35% in 2024. Respondents who are very involved in managing their retirement savings increased significantly from 21% to 50%. 'This research underscores the urgent need for innovative retirement solutions that address both income security and health-related financial risks,' said Hironori Takahashi, Chief Executive Officer, RGA Japan. 'The findings reveal significant opportunities for the insurance industry to develop tailored solutions that address the evolving needs and enhance financial security for Japan's rapidly aging population of retirees.' 'This report provides insights on the generational differences in retirement preparedness,' said R. Dale Hall, FSA, MAAA, CERA, CFA, Managing Director of Research, SOA Research Institute. 'Our study reveals that while 59% of Retirees review their social pension benefits, only 23% of Pre-Retirees and 17% of Prime Age Workers do so. Also, 37% of Prime Age Workers and 45% of Pre-Retirees haven't done any retirement planning at all. We encourage proactive retirement strategies across all age groups, working with employers, insurers, and policymakers.' The full report offers in-depth analysis of retirement perceptions, planning behaviors, income sources, and risk management strategies, providing a comprehensive view of retirement readiness in Japan. For more information about the study, access the full report. About RGA Reinsurance Group of America, Incorporated (NYSE: RGA) is a global industry leader specializing in life and health reinsurance and financial solutions that help clients effectively manage risk and optimize capital. Founded in 1973, RGA is today one of the world's largest and most respected reinsurers and remains guided by a powerful purpose: to make financial protection accessible to all. As a global capabilities and solutions leader, RGA empowers partners through bold innovation, relentless execution, and dedicated client focus — all directed toward creating sustainable long-term value. RGA has approximately $4.0 trillion of life reinsurance in force and assets of $128.2 billion as of March 31, 2025. To learn more about RGA and its businesses, please visit or follow RGA on LinkedIn and Facebook. Investors can learn more at About the Society of Actuaries With roots dating back to 1889, the Society of Actuaries (SOA) is the world's largest actuarial professional organization with more than 34,000 actuaries as members. The SOA's vision is for actuaries to be the leading professionals in measuring and managing risk. To learn more, visit The SOA Research Institute provides objective, data-driven research bringing together tried and true practices and future-focused approaches to address societal challenges and your business needs. It provides trusted knowledge, extensive experience and new technologies to help effectively identify, predict and manage risks. Visit